|Bid||72.95 x 800|
|Ask||72.95 x 800|
|Day's Range||71.51 - 74.22|
|52 Week Range||60.14 - 83.88|
|Beta (3Y Monthly)||1.03|
|PE Ratio (TTM)||23.98|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||2.00 (2.70%)|
|1y Target Est||92.76|
The hemp industry could get a big boost if Congress signs into law a farm bill that eases restrictions on legal hemp and helps make hemp products available at big retailers like Walmart and Walgreens. Yahoo Finance’s Alexis Christoforous speaks to Vertical President Smoke Wallin.
Is CVS Health Corporation (NYSE:CVS) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from industry insiders. They sometimes fail miserably but historically their consensus stock picks outperformed the market […]
The latest list of new buys by the best mutual funds shows a focus on large cap stocks like Berkshire, led by Warren Buffett, CVS, Starbucks and Adobe.
Walgreens Boots Alliance Inc. has teamed up with FedEx Corp. to launch a nationwide next-day prescription home-delivery service as the drugstore chain works to stave off competition from Amazon.com Inc. and other rivals. Under the delivery service called Walgreens Express, patients enrolled in text alerts will receive text notification when qualifying prescriptions are ready, Walgreens said Thursday. For a $4.99 fee, patients can have their prescriptions delivered by FedEx to their home as early as the next day.
CVS Health (CVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In the race to make inroads in the on-demand drug delivery space, Walgreens' move could potentially put it head-to-head with Amazon.com Inc, which earlier this year said it would buy online pharmacy PillPack. Amazon's entry in the market would rattle traditional drug retailers and could potentially disrupt major players the U.S. drug supply chain. Rival CVS Health Corp launched its own next-day delivery service earlier this year.
Walgreens is joining rival drugstore chain CVS Health in expanding home deliveries for prescriptions nationwide, as stores continue adjusting to a retail world made more consumer-friendly by online competition. Walgreens said Thursday it will partner with FedEx to deliver prescriptions as soon as the next day for a $4.99 fee, and it also is providing same-day deliveries in several cities including New York, Chicago and Dallas. Walgreens and FedEx Corp. began a partnership last year where the drugstore chain started offering package drop-off and pick-up services at several thousand stores.
Walgreens Boots Alliance said on Thursday it would partner with FedEx Corp to launch a next-day delivery service for prescription drugs nationwide, giving it a leg up as Amazon threatens to shake-up the sector. In the race to make inroads in the on-demand drug delivery space, Walgreens' move could potentially put it head-to-head with Amazon.com Inc, which earlier this year said it would buy online pharmacy PillPack. Amazon's entry in the market would rattle traditional drug retailers and could potentially disrupt major players the U.S. drug supply chain.
The company announced a new pricing model for its pharmacy benefit management services Wednesday morning. The White House has been an active critic of PBMs, which negotiate drug discounts on behalf of employers and health plans, arguing that they have distorted the drug-pricing system. Drugmakers pay rebates than can amount to more than 50 percent of a drug’s sticker price to secure favorable coverage on PBM drug lists, and critics contend that firms like CVS keep an excessive slice of those undisclosed payments.
Ryan McQueeney discusses the latest drama in the U.S.-China trade war, new developments in Les Moonves' departure from CBS, and a new drug pricing plan from pharmacy giant CVS.
"There's a way to get all of that digitally on your phone," along with the coupons and extra bucks rewards, CVS CEO Larry Merlo tells CNBC's Bertha Coombs.
CVS Health Corp. announced Wednesday that CVS Caremark, its prescription benefit management (PBM) subsidiary, will be rolling out a new model of pricing it says will offer greater "drug cost predictability and pricing simplicity." Under the model, CVS plans to pass through 100% of drug rebates to its health plan clients and says it will be accountable for the impact of drug price inflation and shifts in drug mix. CVS, which completed its $69 billion acquisition of health insurer Aetna last week, said it would begin rolling out the new model starting in 2019. PBMs and the rebates they receive from drug companies have come under increasing scrutiny and criticism in the past two years, with policymakers and clients calling for greater transparency of their financial arrangements. Shares of CVS have increased 8.8% in the year to date, while the S&P 500 has gained 1%.
The "guaranteed net cost" option could also deflect growing criticism that pharmacy benefit managers (PBMs) reap gains off the widening gap between pharmaceutical list prices and their lower net cost after hefty rebates paid by drugmakers to secure coverage and access to their products. President Donald Trump, who has promised lower prescription drug costs for U.S. consumers, earlier this year singled out industry "middlemen", such as PBMs and insurers, and the common practice of drugmakers offering rebates to them.
Guaranteed Net Cost model offers drug cost predictability and pricing simplicity, enabling clients to maximize the impact of PBM cost management strategies Under new model, 100 percent of rebates are passed ...
** A federal judge who has been asked to sign off on the U.S. government's decision to approve CVS Health Corp's acquisition of insurer Aetna Inc said he was "less convinced" than the government that the companies had struck a deal that ensured the merger was legal under antitrust law. ** Debt-laden Indian carrier Jet Airways Ltd is close to finalising a deal under which shareholder Etihad Airways will inject fresh funds, news channel CNBC-TV18 reported, citing sources. ** U.S. oil and gas company Chevron has decided to launch the sale of its stake in Azerbaijan's largest oil field as well as the Baku-Tbilisi-Ceyhan (BTC) pipeline, it said in a statement.
A federal judge who has been asked to sign off on the U.S. government's decision to approve CVS Health Corp's (CVS.N) acquisition of insurer Aetna Inc said Tuesday he was "less convinced" than the government that the companies had struck a deal that ensured the merger was legal under antitrust law. Judge Richard Leon of the U.S. District Court for the District of Columbia had complained last week in a hearing that the two sides had treated him as a "rubber stamp" for the agreement. "At this stage, I am less convinced of the sufficiency of the government's negotiated remedy than the government is," he wrote in the order issued on Tuesday.
Shares of Walgreens Boots Alliance (WBA) touched a new 52-week high Tuesday morning as investors began to digest the possibilities of what its partnership with grocery power Kroger (KR) might do to boost traffic as it expands its reach in the quickly changing retail age.
WOONSOCKET, R.I., Dec. 4, 2018 /PRNewswire/ -- CVS Pharmacy, the retail division of CVS Health (CVS), announced today that it has completed the rollout of time delay safes in all of its 77 CVS Pharmacy locations in Kentucky. The safes will help prevent pharmacy robberies and combat the ongoing opioid epidemic by helping to prevent diversion of controlled substance narcotic medications by keeping them out of the hands of unauthorized individuals.
The following are the top stories in the Wall Street Journal. - A U.S. federal judge on Monday sharply questioned the Justice Department's decision to green-light CVS Health Corp's nearly $70 billion acquisition of Aetna Inc, and said he may order CVS to halt its integration of Aetna's assets while he considers the merger's implications. - U.S. President Donald Trump appointed U.S. Trade Representative Robert Lighthizer, a China hard-liner, to lead the next round of U.S.-China talks, after the sides agreed to a trade truce while they negotiate difficult issues.
WASHINGTON—A federal judge on Monday sharply questioned the Justice Department’s decision to green-light CVS Health Corp.’s nearly $70 billion acquisition of Aetna Inc., and said he may order CVS to halt its integration of Aetna’s assets while he considers the merger’s implications. It is highly unusual for a judge to make such an announcement, since Justice Department antitrust enforcers had approved the deal in October under the condition the companies sell Aetna’s Medicare drug business to preserve competition. When the Justice Department identifies concerns with a merger—and reaches an agreement with the merging companies to address them—a federal law called the Tunney Act requires the government to file the proposed settlement for approval by a federal court, which determines whether the deal is in the public interest.